Tristar Wellness Solutions Inc.

TriStar Wellness Solutions, Inc. develops, markets, and sells wound care products. The company also offers skincare and other products under the Beaute de Maman name for pregnant and nursing women; bleeding and wound management products for surgical, health care, consumer, and military markets; and develops and markets Delivery Devise with Invertible Diaphragm, which is a medical applicator for delivering medicants and internal devices within the body without producing injury or damage. In addition, it develops over-the-counter itch suppression products; and develops, manufactures, and markets wound care and infection control medical devices. The company was formerly known as BioPack Environmental Solutions, Inc. and changed its name to TriStar Wellness Solutions, Inc. in January 2013. TriStar Wellness Solutions, Inc. is based in Portland, Oregon. On January 15, 2016, TriStar Wellness Solutions, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Oregon.

Tristar Wellness Solutions Inc. trades as TWSI on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Tristar Wellness Solutions Inc. can be compared against peers such as Australis Capital Inc., Ayr Wellness Inc., Cannabis Bioscience International Holdings, Inc., CV Sciences, Inc., Delivra Health Brands Inc., Full Alliance Group, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $42,000, beta of 9.91, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

TWSI currently shows total debt of N/A and beta of 9.91. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.tstarwellness.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.